Accessed May 5, 2021. Moderna has generated ($1.55) earnings per share over the last year. Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More May. Create a personalised ads profile. You can learn more about the standards we follow in producing accurate, unbiased content in our. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. QUANT RANKS. The offers that appear in this table are from partnerships from which Investopedia receives compensation. Accessed May 6, 2021. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Store and/or access information on a device. See what's happening in the market right now with MarketBeat's real-time news feed. It is making additional investments in order to increase global supply to up to 3 billion doses in 2022. The consensus earnings estimate was $2.04 per share on revenue of $2.2 billion. MRNA: Get the latest Moderna stock price and detailed information including MRNA news, historical charts and realtime prices. Develop and improve products. TradingView UK. Accessed May 5, 2021. Next reporting date: August 11, 2021: EPS forecast (this quarter) $6.13: Annual revenue (last year) $803.4M: Annual profit (last year)-$747.1M: Net profit margin October 29, 2020. Moderna's next earnings report (for Q2 FY 2021) is estimated to be released on Aug. 3, 2021. The chart below shows up to four years of a company's earnings history. The company offered no forward earnings or revenue guidance in its earnings press release. Moderna Inc (MRNA) Q3 2019 Earnings Call Transcript MRNA earnings call for the period ending September 30, 2019. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. The reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.04 by $0.80. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. if the earnings are exceptionally great, it may take the grey way, with potential ATH just shy of 300. The TeenCOVE Study showed a vaccine efficacy rate of 96%, and no serious safety concerns were identified. Get short term trading ideas from the MarketBeat Idea Engine. FOR INSTITUTIONS. Moderna has already signed advanced purchase agreements for scheduled delivery of its vaccine in 2021 worth a total of $19.2 billion, which includes the $1.7 billion in sales of the vaccine already recorded in Q1 FY 2021. Learn about financial terms, types of investments, trading strategies and more. Revenue for the quarter came in slightly below analysts' estimates. Learn more about MRNA stock and its outlook here. MRNA: Moderna, Inc. - Earnings Announcements. Its quarterly revenue was up 24112.5% compared to the same quarter last year. Export data to Excel for your own analysis. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Nasdaq 100. Moderna, Inc. MRNA is scheduled to report first-quarter 2019 results on May 7, before market open. These include white papers, government data, original reporting, and interviews with industry experts. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Moderna Inc. "Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates." He received his bachelor's degree in interdisciplinary studies from St. Stephen's University and his master's degree in economics at The New School for Social Research. The firm earned $1.94 billion during the quarter, compared to analysts' expectations of $2.48 billion. Measure content performance. Triple play is a term for a stock that simultaneously beats analyst expectations for revenue and earnings and raises earnings guidance for future quarters. Moderna's EPS beat analyst forecasts by a significant margin. "Earnings Calendar: MRNA." Please log in to your account or sign up in order to add this asset to your watchlist. Add to Watchlist. Moderna's revenue of $1.9 billion, which was up significantly from the $8 million posted in the year-ago quarter, was driven by sales of its COVID-19 vaccine. Start Your Risk-Free Trial Subscription Here, Blowout Results May Not Sustain Targetâs RallyÂ, Under Armour Shares Gap Lower As Judge OK's Shareholder Lawsuit, The Container Store Has What Every Growth Stocks NeedsÂ, Donât Rush To Buy Walmart, Extra Low Prices Are On The WayÂ, Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors, Steel Producers Extend Their One-Year Gains On Strong Demand, Lumentum Stock Providing Opportunistic Pullbacks, 7 Cyclical Stocks That Can Help You Play Defense, 7 Stocks That Could Benefit From a Capital Gains Tax Hike, 7 Forever Stocks That Are Never Bad to Buy, 7 Stocks That Still Have Upside For Investors to Buy, 7 Precious Metals Stocks That Will Keep Your Portfolio On Trend, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, Receive Analysts' Upgrades and Downgrades Daily. IPO Calendar. The company is a frontrunner among the biotechs working on ⦠Identify stocks that meet your criteria using seven unique stock screeners. List of Partners (vendors), Source: Predictions based on analysts' consensus from Visible Alpha. In depth view into MRNA (Moderna) stock including the latest price, news, dividend history, earnings information and financials. Investopedia requires writers to use primary sources to support their work. © American Consumer News, LLC dba MarketBeat® 2010-2021. Learn more about MarketBeat. October 29, 2020. Investors will be watching how sales of mRNA-1273 bolster Moderna's financial results when the company reports earnings on February 25, 2021 for Q4 FY 2020.  INTERVIEWS. Q1 2021 Earnings Release. Q2 2020 (Jun 2020) EPS of -$0.31 beat by $0.05 Revenue of $66.35M (407.15% YoY) beat by $42.11M. CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the ⦠He teaches macroeconomics at St. Stephen's University. August 5, 2020. To see all exchange delays and terms of use please see disclaimer. The price-to-sales (P/S) ratio compares a company's stock price to its revenues, helping investors find undervalued stocks that make good investments. View live MODERNA INC chart to track its stock's price action. I expect it to go the green way, reaching 220âs-240âs, after which the profit-taking spree will bring it back to 180âs or lower. 12, 2021 at 2:35 p.m. Disclaimer: The TipRanks Smart Score performance is based on backtested results. Moderna, Inc. Common Stock (MRNA) Nasdaq Listed. Article Sources Investopedia requires writers to use primary sources to support their work. API for Institutions. Finance. Education Center. Moderna updates 2020 outlook, and now expects positive net cash provided by operating activities and used for purchases of property and equipment to be between $0.1 billion and $0.3 billion, driven by customer deposits of approximately $1.2 billion received year-to-date as of September 30, 2020 . Stock Market Holidays. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. What do we know about their efficacy? All rights reserved. He is an expert on company news, market news, political news, trading news, investing, and the economy. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. We also reference original research from other reputable publishers where appropriate. Add to Portfolio. Moderna Inc. ( NASDAQ: MRNA) Q2 2020 earnings call dated Aug. 05, 2020. Apply market research to generate audience insights. Want to see which stocks are moving? The dark blue line represents the company's actual earnings per share. Fundamental company data provided by Zacks Investment Research. Moderna reiterated in its earnings press release a previous increase to its forecast of future supply of its COVID-19 vaccine. Find earnings report and search by company, date and market cap. The company plans to supply a total of between 800 million and 1 billion doses of the vaccine in 2021. Earnings Calendars. -6.31 (-3.97%) DATA AS OF May 12, 2021. "Price Chart: MRNA and S&P 500." $152.68. Check out the Markets Insider earnings calendar. âThere is a race to get the public vaccinated, so we are willing to take more risk.' Could mRNA COVID-19 vaccines be dangerous in the long-term? Q1 2020 (Mar 2020) EPS of -$0.35 beat by $0.01 Revenue of $8.39M (-47.65% YoY) ⦠The company's shares fell more than 5% in pre-market trading. View the latest Moderna Inc. (MRNA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Receive a free world-class investing education from MarketBeat. View our full suite of financial calendars and market data tables, all for free. Owner earnings run rate is an extrapolated estimate of an owner's earnings (free cash flow) over a defined period of time (typically a year). View which stocks are hot on social media with MarketBeat's trending stocks report. Find the latest Moderna, Inc. (MRNA) stock quote, history, news and other vital information to help you with your stock trading and investing. Revenue narrowly missed analyst expectations. Measure ad performance. Select personalised content. Moderna has generated ($1.55) earnings per share over the last year. Earnings Forecasts and Valuation Moreover, earnings forecasts for 2021 and 2022 put MRNA stock on a reasonable valuation despite its recent ⦠HOW TO USE TIPRANKS. Revenue grew 22,989.8% on a year-over-year basis. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Moderna has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 4th, 2021 based off prior year's report dates. TradingView. See who is reporting this week. Moderna Inc (NASDAQ: MRNA) is a coronavirus vaccine play that has seen its shares rally close to 160% year-to-date. 2020 Financial Update. Matthew Johnston has more than 5 years writing content for Investopedia. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Finovate. Create a personalised content profile. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Select personalised ads. Dividend Calendars. $2.84. Moderna Inc. ( NASDAQ: MRNA) Q3 2020 earnings call dated Oct. 29, 2020. CNBC. FY Report Date: 12/2021: Last Quarter's Earnings: 2.84: Year Ago Earnings-1.57: Current Quarter's Estimate: 6.13: Current Year's Estimate: 25.26: Median PE on CY Estimate: N/A: Next ⦠The company agreed to supply 7 million doses of booster vaccine in 2022 with an additional option to deliver another 7 million doses in the second half of 2022 or during the first quarter of 2023. Swissmedic authorized Moderna's vaccine for use in Switzerland on Jan. 12, 2021. Moderna has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 4th, 2021 based off prior year's report dates. Use precise geolocation data. Next Earnings Date-Last Earnings Date-Annual Dividend (Yield)-Options-Fundamentals. Moderna Earnings Estimates and Actuals by Quarter Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. As to the Phase 3 study, in its earnings release Moderna said "enrollment is on track to complete in September." P/E Ratio-PEG Ratio-Price to Book-Price to Cash Flow-Price to Free Cash Flow-Total Sales (TTM)-Revenue per Share (TTM)-Shares Outstanding-Share Float (%)-% Held by Institutions -Dividends per Share-Dividend Date- $0.82 to $5.56-$0.35. Financial analysis is the process of assessing specific entities to determine their suitability for investment. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Moderna last announced its quarterly earnings data on May 6th, 2021. YouTube. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Date Event description Earnings per share actual Earnings estimate range Previous year's actual; May 6, 2021. Find market predictions, MRNA financials and market news. Actively scan device characteristics for identification. Stay up to date with lastest Earnings Announcements for Moderna, Inc. from Zacks Investment Research Data is currently not available. Get daily stock ideas top-performing Wall Street analysts. long-awaited reversal brought MRNA to previous highs. In the last reported quarter, the company delivered a positive earnings surprise of 13.95%. Moderna Inc. "Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses." Value investors like Warren Buffett select undervalued stocks trading at less than their intrinsic book value that have long-term potential. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Total revenue was $571 million for Q4 2020, compared to $14 million for the same period in 2019. A nurse draws a Moderna coronavirus disease (COVID-19) vaccine, at East Valley Community Health Center in La Puente, California, March 5, 2021. Select basic ads. Moderna (MRNA) Financial Results: Analysis, Price-to-Sales Ratio (P/S Ratio) Definition, Value Investing: How to Invest Like Warren Buffett, What Quarters (Q1, Q2, Q3, and Q4) Tell Us, Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates, Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses. much, of course, will depend on the earnings in 2 days. Build a Quant Strategy. Looking for new stock ideas? Moderna also noted that it has completed the second of three phases of testing for its COVID-19 vaccine in adolescents ages 12-17. Over the past year, Moderna's shares have provided a total return of 230.0%, well above the S&P 500's total return of 45.3%.
Leicester City Vs Fulham Today,
Cliffs Shoes Flats,
Casa C-101 For Sale,
Woolworths Code Of Conduct 2020,
Man City Garden Gnome,
Sutton Sports Village Soft Play,
Astra Giurgiu Vs Dinamo Bucuresti Prediction,
Exterior Painter And Decorator Near Me,
Philippine Educational Theater Association Vision,
Republic Fitness Personal Training,